Delivery Order SPE2DB22D3016-SPE2DB25FBAS8
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Mounjaro 2.5 mg/0.5 mL pen injectors valued at $7,226.22 with a firm fixed price structure. The contract, awarded on September 16, 2025, with an ultimate completion date of September 17, 2025, represents a non-competitive set-aside delivery against AmerisourceBergen's existing indefinite delivery contract vehicle. Performance will occur at the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $5,758.57 firm fixed-price delivery order on August 14, 2025, for Mounjaro 2.5 mg/0.5 mL pen injections, with an ultimate completion date of August 15, 2025. The contract, issued without set-aside designation, represents a competitively awarded procurement executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a $1,360.45 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro 15 mg/0.5 mL pen injections on July 22, 2025, with an ultimate completion date of July 23, 2025. The contract, which carries no set-aside designation, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with the federal...
- The Defense Logistics Agency has awarded a delivery order valued at $2,223.89 to AmerisourceBergen Drug Corp for the supply of Mounjaro 10 mg/0.5 ml pen injections. This is a firm fixed-price delivery order with an ultimate completion date of August 19, 2025, issued on August 18, 2025. The contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $16,325.40 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 ml pen injectors on August 26, 2025, with completion expected by August 27, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication, consistent with AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $4,401.61 to supply Mounjaro 2.5 mg/0.5 mL pen injections, with delivery to be completed by August 4, 2025. This competitively awarded, firm fixed-price delivery order was issued on August 1, 2025, with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 12.5 mg/0.5 mL pen injectors on August 28, 2025, with a ceiling value of $5,441.80. This non-competitive delivery order, valued at firm fixed price, is set to be completed by August 29, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a single delivery transaction under the company's existing contract vehicle with the DLA....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $2,448.81 on July 21, 2025, for the supply of Mounjaro 5 mg/0.5 mL pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 22, 2025, to be performed at the contractor's location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. As a child contract action, this delivery order falls under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $3,069.43 delivery order to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 ml pen injections with an ultimate completion date of June 2, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's broader pharmaceutical supply agreements with DLA. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors on September 5, 2025. This competitively awarded, non-set-aside contract has a ceiling value of $3,069.11 and is structured as a firm fixed price delivery order with an ultimate completion date of September 8, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBAS8Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 2.5 mg/0.5 mL pen injections valued at $16,657.00, with a completion date of July 1, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued competitively to the pharmaceutical distributor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical vendor within the DLA's medical supply chain, delivering pharmaceutical products to support federal healthcare programs. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle valued through December 2026. The IDC enables the company to supply a comprehensive range of pharmaceutical products and medical commodities to support military healthcare operations worldwide, including support to the Defense Health Agency and other federal healthcare systems. Mounjaro, a diabetes medication, aligns with AmerisourceBergen's extensive portfolio of brand-name and generic medications delivered through DLA contracts, demonstrating the company's capability to fulfill specialized pharmaceutical requirements across multiple therapeutic domains in support of military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.7k | 6/30/25 |